Ginkgo Bioworks Holdings, Inc. Class A DNA 深 沪
已收盘 08-14 16:00:00 美东时间
6.79
-0.450
-6.22%
华盛通- 最 高7.20
- 今 开7.20
- 成交量 145.09万股
- 最 低 6.775
- 昨 收 7.24
- 总市值 4.57亿
- 52周最高 17.58
- 市盈率 静 --
- 换手率 2.15%
- 52周最低 5.37
- 委 比 -60.92%
- 总股本 6734.03万
- 历史最高 634.56
- 量 比 1.11
- 振 幅 5.87%
- 历史最低 5.00
- 每 手 1
- 风险率 2.17%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
TD Cowen Downgrades Ginkgo Bioworks Holdings to Hold, Lowers Price Target to $9
TD Cowen analyst Brendan Smith downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Hold and lowers the price target from $12 to $9.
08-08 04:30
U.S. CDC Says Will Enhance Screening And Monitoring Of Travelers Arriving From Areas Affected By Ebola Outbreaks; Will Coordinate With Airlines, Others To Manage Travelers Who May Have Already Been Exposed To Ebola; Will Enhance Contract Tracing, Hospital Readiness Nationwide
https://www.cdc.gov/ebola/situation-summary/index.html
05-18 23:25
电话会总结 ｜ Ginkgo Bioworks(DNA)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Ginkgo Bioworks 2026年第一季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度营收为1900万美元，同比下降49%。剔除2025年第一季度BiomEdit协议终止产生的750万美元非现金收入后，调整后营收同比下降37%。 **亏损情况：** 持续经营业务净亏损7600万美元，较2025年第一季度的8300万美元有所改善，主要得益于重组措施。 **调整后EBITDA：** 负4200万美元，较去年同期负4400万美元略有改善。值得注意的是，该指标现包含1600万美元的闲置租赁空间
05-09 12:12
Ginkgo Bioworks Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.
Ginkgo Bioworks Holdings shares are trading lower after the company reported wo...
05-08 05:23
ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced its AI
04-08 20:02
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
BTIG Maintains Sell on Ginkgo Bioworks Holdings, Lowers Price Target to $5
BTIG analyst Mark Massaro maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and lowers the price target from $9 to $5.
03-12 19:12
Elon Musk Endorses 'Fundable' Jurassic Park: These De-Extinction Companies Are Already Making It Happen
Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinosaurs yet, but they are bringing extinct items back to life.
03-08 04:01
Ginkgo Bioworks Rolls Out Ginkgo Cloud Lab
Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web
03-02 21:08
